London, June 25-26
Presenting the annual Healthtech Summit, June 25-26, 2013 in London, to be held at NYSE Euronext with 100+ delegates and 20 presenting CEOs from the top emerging healthtech companies across all stages. The theme for this years edition will be “Crossing the chasm from start-up to a sustainable high growth business.” European technology companies in this sector can apply to present at the event by clicking here and delegates can find more information on registration by clicking here.
Aris Constantinides, Founder and Investment Director of NBGI Ventures, will serve as Co-President of the Healthtech Summit and commented on the state of the industry in Europe and the particular choice of theme for this year’s event, “The healthcare landscape is changing globally and on many levels: regulatory, economic, and technological. We chose the particular theme to this year’s summit as, amongst these strong winds of change, entrepreneurs are increasingly required to build their companies into real, sustainable and successful high growth businesses. Aside from highlighting Europe’s 20 most promising healthtech companies, this year’s Summit is aimed at helping entrepreneurs overcome these important challenges and thinking about building for the long-term.”
Rudy Mareel, former CEO of Synthon and Co-President of the Healthtech Summit explained his vision and goals for the upcoming Summit saying, "Innovation is poised to play a greater role in the evolution of the healthcare market as demographic, regulatory and financial challenges play out. Yet, new product and services concepts often struggle to gain momentum in the larger institutions. Entrepreneurs, in contrast, have the freedom to develop ideas, but are faced with limited resources that can just as easily stifle their innovations. That is why we have designed The Healthtech Summit as a space for young companies and resources to meet. We look forward to robust interaction between technology innovators, leaders of the various venture capital groups who invest in healthcare and key players from the industry."
Interview with Rudy Mareel and Aris Constantinides
Co-Presidents, Healthtech Summit 2013:
What does this event bring to the table that other events are lacking?
Rudy: This is the 4th Healthtech Summit and the Tech Tour has refined the process to select the top 20 Healthtech companies in Europe. The Selection Committee is chosen from top VC's and thought leaders in the industry. Companies are then nominated by the Selection Committee or apply via an open application online and are then screened by 2-3 Committee members to ensure that companies that are selected by merit only. Such a clear and defined process run by professionals in the industry simply produces great quality companies and leads to more deal flow at the event itself. The event also has a capped attendance that is regulated for quality and ensures a more intimate meeting of corporates, VC's, and CEO's, to network with.
Aris: The Tech Tour works through a volunteer model for every Summit, so that the team changes and generates fresh ideas and a different dynamic, while also building on the knowledge of previous Summits. Tech Tour events are essentially created by VC's for VC's and you can see that by the way the program is run.
What are your goals and objectives as the President of this year's Tech Growth Summit?
Rudy: The purpose of the Healthtech Summit is to create connections. I will be satisfied when the young companies that attend walk away with potential investors interested in following up. I want our Venture Capital and Business Development participants to have a short list of targets identified that might otherwise have taken more time and attention to generate. In summary, my short term objective is for people to form mutually beneficial connections; my long-term objective is for those connections to bear fruit in terms of value in the healthcare market.
Aris: The purpose of the Summit is two-fold: highlighting Europe and Israel's 20 most promising companies in terms of potential to become high growth and valuable stand alone businesses and to help their management teams address the multiple challenges they face in today's environment. To meet these goals we have put together a great program of high-level keynote speakers, panelists, and one-to-one networking sessions.
What major trends do you see emerging from the healthtech market?
Rudy: The most important trends now are toward embedding technology more profoundly in medical treatment and devices – everything gets “smart” and more interconnected. Beyond this, Europe continues to lag behind the U.S. when it comes to the entrepreneurial stage of innovation and business development; this despite the fact that, in much of Europe, regulatory barriers to new products are actually lower than in America. The Healthtech Summit is meant to start a shift in this trend toward a richer early-stage ecosystem for Europe.
Aris: We are going through a period of transition in healthcare driven by regulation, pressure, and demographics and facilitated by technology and innovation. I believe the next decade will prove to be particularly transformative for the delivery of healthcare and will create significant opportunities for bold and visionary entrepreneurs to develop new paradigms and generate incredible value.
What benefits can healthtech companies gain from basing their start-ups in Europe?
Rudy: The standout benefit for start-ups in Europe is lower regulatory hurdles for new products. While this is not uniform across the continent, the diversity of market opportunities within Europe enables companies to quickly shift focus to more promising countries or regions.
Aris: Europe can be an excellent base for growing healthcare companies and being the eco-system in which they operate. Europe is already developed and robust and has excellent and experienced investors that are willing to take early stage risk, leading clinicians that are pioneering the field, and mature organizations and institutions that are willing to consider new paradigms or technologies that promise to lower costs and improve clinical outcomes. All of these factors contribute to Europe being an excellent base to launch and sustain promising healthtech companies.